INTIAL STUDY - Indolent Non-Hodgkin's ImmunoradioTherapy Initiated Approach in Lymphoma

This study is for people newly diagnosed with a slow-growing type of non-Hodgkin's lymphoma (a cancer of the lymph system). It tests a treatment called radioimmunotherapy using a radioactive antibody called I-131 rituximab, followed by further doses of the same antibody without the radioactive tag. This avoids the need for standard chemotherapy, which can cause significant side effects. Previous studies suggest this approach can achieve high rates of complete remission with fewer toxic effects. You may be eligible if: - You are 18 years of age or older - You have been diagnosed with a low-grade or follicular B-cell non-Hodgkin's lymphoma (confirmed by biopsy) - Your lymphoma is at Stage IIB, III, or IV - You have not previously received chemotherapy, radiotherapy, or immunotherapy for lymphoma - Your general health and organ function are within required levels - You can attend the treatment centre for follow-up You may NOT be eligible if: - You are pregnant, breastfeeding, or sexually active without effective contraception (if you are a woman of childbearing age) - Your lymphoma has spread to the brain or spinal cord - Your blood counts or organ function are below required levels - You have significant heart, kidney, or liver disease - You have another active cancer (within the last 5 years, with some exceptions) - You are on long-term steroid treatment for any condition Talk to your doctor about whether this trial might be right for you.